Emmaus Life SciencesEMMA -16.67% Market Cap is $0.70 Mil as of Jun. 26, 2026. The stock has 6 warning signs investors should review. Among 1,431 Biotechnology companies, Emmaus Life Sciences ranks worse than 98.18% on this metric.
Emmaus Life Sciences's quarterly market cap
increased
from Sep. 2025 ($0.70 Mil) to Dec. 2025 ($0.91 Mil) and
increased
from Dec. 2025 ($0.91 Mil) to Mar. 2026 ($1.05 Mil).
Emmaus Life Sciences's annual market cap
declined
from Dec. 2023 ($6.19 Mil) to Dec. 2024 ($0.54 Mil) but then
increased
from Dec. 2024 ($0.54 Mil) to Dec. 2025 ($0.91 Mil).
Enterprise Value is the theoretical takeover price. It is more comprehensive than market capitalization (market cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash and cash equivalents. Emmaus Life Sciences's Enterprise Value for Today is $31.89 Mil.
Emmaus Life Sciences (OTCPK:EMMA) Market Cap Explanation
Market cap is not the real price you pay for a company. If you buy the company and become its owner, you become the owner of the cash the company has, and you also assume the companys debt. The real price you pay is the Enterprise Value.
Warren Buffett uses the ratio of total market cap of all public traded companies over GDP to measure if the market is expensive. As of April 2012, the US total market cap is about $14.7 trillion, while the US GDP is about $15 trillion. The market was modestly overvalued.
Emmaus Life Sciences Market Cap Related Terms
Emmaus Life Sciences Market Cap Historical Data
* Premium members only.
The historical data trend for Emmaus Life Sciences's Market Cap can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Emmaus Life Sciences's Market Cap, along with its competitors' market caps and Market Cap data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Emmaus Life Sciences Market Cap vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Emmaus Life Sciences's Market Cap distribution charts can be found below:
* The bar in red indicates where Emmaus Life Sciences's Market Cap falls into.
Market cap is the short version of market capitalization. It is the total market value to buy the whole company. It is equal to the share price times the number of shares outstanding.
Emmaus Life Sciences's Market Cap for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Emmaus Life Sciences (EMMA) has a Market Cap of $0.70 Mil as of Jun. 26, 2026. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on Emmaus Life Sciences and its competitors. According to the industry distribution chart, Emmaus Life Sciences ranks #1405 out of 1431 companies in the Biotechnology industry, placing it in the top 98.2%.
Is Emmaus Life Sciences' Market Cap too high?
Emmaus Life Sciences' current Market Cap is $0.70 Mil. The Biotechnology industry median Market Cap is 117.63. Emmaus Life Sciences' value of $0.70 Mil is 99.4% below this industry median. Based on the distribution chart, Emmaus Life Sciences ranks #1405 out of 1431 companies in the Biotechnology industry, which is in the bottom quartile relative to peers.
How does Emmaus Life Sciences' Market Cap compare to CERO and AGTX?
According to the Biotechnology industry distribution chart, Emmaus Life Sciences ranks #1405 out of 1431 companies for Market Cap. This places Emmaus Life Sciences in the lower half of its industry. The industry median Market Cap is 117.63. Emmaus Life Sciences' value of $0.70 Mil is 99.4% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Market Cap for a Biotechnology company?
The median Market Cap among Biotechnology companies is 117.63, based on 1,431 companies in the industry. Companies in the top quartile (top 25%) have a Market Cap significantly above this median, while those in the bottom quartile fall well below. However, Market Cap should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Emmaus Life Sciences's current Market Cap of $0.70 Mil is 99.4% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Market Cap mean?
A high Market Cap can signal that a stock is expensive relative to its fundamentals. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on Emmaus Life Sciences and its competitors. For the Biotechnology industry, the median Market Cap is 117.63 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Emmaus Life Sciences's current Market Cap is $0.70 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Emmaus Life Sciences stock overvalued right now?
Based on GuruFocus' analysis, Emmaus Life Sciences (EMMA) is currently considered Fairly Valued. The stock's GF Value™ is $0.01, compared to a current price of $0.01 — trading right at its estimated fair value. The current Market Cap is $0.70 Mil and 99.4% below the Biotechnology industry median of 117.63. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Market Cap calculated?
Market Cap is calculated from a company's financial statements. For Emmaus Life Sciences (EMMA), the current Market Cap is $0.70 Mil as of Jun. 26, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Emmaus Life Sciences Inc is a commercial-stage biopharmaceutical company engaged in the discovery, development, marketing and sales of the Company's product Endari (prescription grade L-glutamine oral powder), to reduce the acute complications of sickle cell disease (SCD) in adult and pediatric patients five years of age and older. Endari is reimbursable by the Centers for Medicare and Medicaid Services, and every state provides coverage for Endari for outpatient prescriptions to all eligible Medicaid enrollees within their state Medicaid programs. Endari is also reimbursable by many commercial payors.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
EMMA has been successfully added to your 